NCT05137171: AK105 Combined With Anlotinib in Patients With Cervical Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 36 planned
- Started
- 2 May 2022
- Primary completion
- 1 Jul 2025
- Arms
- AK105 and anlortinib
- Results
- None posted
- 30 Nov 2021: Trial registered
- 2 May 2022: Trial started